Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
José Alcides Almeida de Arruda, Mariana Villarroel-Dorrego, Clara Herrera Freire, Ignacio Molina-Ávila, Juan Martin Pimentel-Solá, Gerardo Gilligan, Eduardo Piemonte, René Panico, Juan Cruz Romero Panico, Saray Aranda-Romo, Francisco Javier Tejeda-Nava, Mônica Simões Israel, John Lennon Silva Cunha, Vanessa Alves de Medeiros, Cassiano Francisco Weege Nonaka, Pollianna Muniz Alves, Israel Leal Cavalcante, José Victor Lemos Ventura, Fernanda Silva de Lima, Victor Zanetti Drumond, Lucas Guimarães Abreu, Tarcília Aparecida Silva, Felipe Paiva Fonseca, Ricardo Alves Mesquita, René Martínez-Flores, Karina Cordero-Torres, Richard Ahumada-Ossandón, Jorge Guzmán, Raiza Toro, José Cândido Caldeira Xavier-Júnior, Sebastião Silvério Sousa-Neto, Diego Antônio Costa Arantes, Elismauro Francisco Mendonça, Victor de Mello Palma, Márcia Gaiger de Oliveira, Fernanda Visioli, Karem L Ortega, Jefferson R Tenório, Bruno Augusto Benevenuto de Andrade
BACKGROUND: Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease that may affect the oral mucosa. The variable spectrum of oral lesions observed in SLE can pose challenges in diagnosis, particularly when the lesions occur in isolation. The aim of this study was to describe the oral lesions occurring in patients with SLE from Latin America. METHODS: This collaborative record-based study involving 11 oral and maxillofacial pathology and medicine services across Venezuela, Argentina, Chile, Brazil, and Mexico describes the clinicopathological profile of SLE-related oral lesions...
April 30, 2024: Lupus
#2
JOURNAL ARTICLE
Iveth Eunice García-Cañas, Enrique Cuevas-Orta, David Alejandro Herrera-Van Oostdam, Carlos Abud-Mendoza, Lunpos Group
INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disease that often requires hospitalization. Most hospitalizations are due to infections and/or disease activity, for which several risk factors have been described in non-Mestizo patients. OBJECTIVE: To identify risk factors for hospitalization in patients with systemic lupus erythematosus (SLE). METHODS: This was an observational case-control study of patients with SLE in San Luis Potosí, Mexico, evaluated from January 2019 to October 2020...
April 26, 2024: Lupus
#3
JOURNAL ARTICLE
Erik W Anderson, Marissa Sansone, Bhakti Shah, Myriam Kline, Giovanni Franchin, Cynthia Aranow, Meggan Mackay
OBJECTIVE: Constitutional symptoms (fatigue, lymphadenopathy, and weight loss) are not included in the SLE disease activity index-2000 (SLEDAI-2K). In this pilot study, we assessed the concurrent and construct validity of a revised SLEDAI-2K (SLED-R) that included these symptoms with the original SLEDAI-2K (SLED-O), using the physician global assessment of disease activity (PGA) as the reference. METHODS: Our revised SLED-R substituted the SLED-O's fever descriptor with a constitutional descriptor that included fever, fatigue, lymphadenopathy, and/or weight loss...
April 25, 2024: Lupus
#4
JOURNAL ARTICLE
Jianda Lu, Yuanhao Wu, Jun Xue, Chuanming Hao
BACKGROUND: The current prediction models for the risk of infection during immunosuppressive treatment for lupus nephritis (LN) lack a prediction time window and have poor pertinence. This study aimed to develop a risk stratification to predict infection during immunosuppressive therapy in patients with LN. METHODS: This retrospective nested case-control study collected patients with LN treated with immunosuppressive therapy between 2014 and 2022 in the Nephrology ward in Huashan Hospital affiliated to Fudan University and Huashan Hospital Baoshan Branch...
April 25, 2024: Lupus
#5
JOURNAL ARTICLE
Johannes Cornelis Nossent, Helen Isobel Keen, David Brian Preen, Charles Anoukpar Inderjeeth
AIM: To compare frequency, incidence rates (IR), risk factors and outcomes of a first venous thromboembolic event (VTE) between patients with systemic lupus erythematosus (SLE) and controls. METHODS: Using state-wide longitudinal hospital data from Western Australia (WA), we recorded venous thrombosis (VT) and pulmonary embolism (PE) in patients with SLE ( n = 1854, median age 40, 86% female) and matched hospitalised controls ( n = 12,107, median age 40 years, females 88...
April 24, 2024: Lupus
#6
JOURNAL ARTICLE
Paulina Ramirez, Andres Giglio, Jorge Verdugo, Francisco Gutierrez
INTRODUCTION: Systemic lupus erythematosus (SLE) causes kidney compromise in up to 40% of patients, contributing significantly to morbidity. Lupus nephritis (LN), an early onset manifestation in most patients, is histologically classified into six types, with types III, IV, and V requiring treatment with induction therapies, usually glucocorticoids with mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC). However, up to 60% of patients fail to achieve complete remission, and 27%-66% have subsequent flares...
April 23, 2024: Lupus
#7
JOURNAL ARTICLE
Hongyu Yang, Shuping Wang, Fei Wang, Xuemei Bai, Juan Ren
AIM: This study aimed to investigate the expression of H19 and its possible molecular mechanism in systemic lupus erythematosus (SLE). METHODS: The expression of H19 and miR-19b in serum and peripheral blood mononuclear cells (PBMCs) were detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Receiver operator characteristic (ROC) curve was constructed to evaluate the diagnostic value of serum H19 in SLE. Pearson correlation coefficient was used to analyze the correlation between serum levels of H19 and miR-19b...
April 18, 2024: Lupus
#8
JOURNAL ARTICLE
Maria Schletzbaum, W Ryan Powell, Shivani Garg, Joseph Kramer, Brad C Astor, Andrea Gilmore-Bykovskyi, Amy J Kind, Christie M Bartels
OBJECTIVE: In systemic lupus erythematosus, poor disease outcomes occur in young adults, patients identifying as Black or Hispanic, and socioeconomically disadvantaged patients. These identities and social factors differentially shape care access and quality that contribute to lupus health disparities in the US. Thus, our objective was to measure markers of care access and quality, including rheumatology visits (longitudinal care retention) and lupus-specific serology testing, by race and ethnicity, neighborhood disadvantage, and geographic context...
April 17, 2024: Lupus
#9
JOURNAL ARTICLE
Rina Moriyama, Yasuhiro Katsumata, Yuko Okamoto, Masayoshi Harigai
OBJECTIVE: This study aimed to investigate the role of the programmed cell death protein 1 (PD-1) pathway and T peripheral helper (Tph) cells in the pathogenesis of lupus nephritis using lupus-prone BXSB- Yaa mice. METHODS: Male BXSB- Yaa mice and age-matched male C57BL/6 mice were used. The expression of PD-1 and its ligands (programmed cell death 1 ligand-1, PD-L1 and programmed cell death 1 ligand-2, PD-L2) and the phenotypes of kidney-derived cells and splenocytes expressing these molecules were analyzed by immunofluorescence and flow cytometry...
April 15, 2024: Lupus
#10
JOURNAL ARTICLE
Sharath Gowda, Khushboo Rana, Ankit Kumar, Pradip Kumar Prajapati, Namisha Patel, Sapan Pandya, Ratika Srivastava
Major reason for mortality among systemic lupus erythematosus patients is renal failure due to the deposition of immune complexes in the glomeruli. Being a chronic disease with multiple relapses and remissions across the lifespan, it's important to know the degree of nephritis for diagnosis as well as the long-term clinical management of the patients. Currently, renal biopsy is being used as the gold standard to diagnose and define the stages of the disease. However, renal biopsy being invasive only provides a localized picture of nephritis, and has the risk of bleeding...
April 15, 2024: Lupus
#11
JOURNAL ARTICLE
Pedro Gaspar, Ana Sofia M Fernandes, Ana Mafalda Abrantes, Inês Parreira, Inês Silva, Ryan C Silva, Mariana B Nobre, Joana R Martins, Catarina Mota
OBJECTIVES: We aim to independently assess the validity of the damage index for antiphospholipid syndrome (DIAPS) in thrombotic antiphospholipid syndrome (APS) patients by exploring the prevalence and risk factors of organ damage and evaluating its impact on health-related quality of life (HR-QoL). METHODS: Cross-sectional study including all thrombotic APS patients (Sydney criteria) attending a Portuguese tertiary centre. Damage was assessed using the DIAPS, and HR-QoL using the 3- and 5-level EuroQol HR-QoL (EQ-D5-3L and 5L), and Visual Analogue Scale (VAS) applied via a phone questionnaire...
April 14, 2024: Lupus
#12
JOURNAL ARTICLE
Murugan Sudhakar, Anu P Kocheril, Anish S George, George I Vettiyil, Anitha Jasper, Sathish Kumar
Idiopathic intracranial hypertension (IIH) is a diagnosis of exclusion characterized by features of raised intracranial pressure (ICP) in the absence of brain parenchymal lesion, vascular malformations, hydrocephalus, or central nervous system (CNS) infection. Commonly used other terms for this entity include benign intracranial hypertension (BIH) or pseudotumor cerebri. Few case reports of systemic lupus erythematosus (SLE) presenting as IIH are available in the literature. We report a 12-year-old girl presented with chronic holocranial headache and occasional episodes of projectile vomiting for the last 6 months and then developed blurring of vision for the last month...
April 12, 2024: Lupus
#13
JOURNAL ARTICLE
Paloma Vela-Casasempere, Rocío Caño Alameda, Silvia Gómez Sabater, Silvia Cortell Aznar, Encarnación Pérez Pascual
OBJECTIVE: To share our experience with belimumab in lupus pregnant women and to review the relevant published literature on its use in this scenario. METHODS: A prospective observational study of pregnant patients with lupus was conducted. Additionally, MEDLINE and EMBASE databases were searched, and a secondary hand search of the literature was performed. Studies were evaluated and visualised descriptively. RESULTS: Sixteen pregnancies of 12 lupus women were included, six (involving eight pregnancies) received belimumab throughout their illness, five of them during some period of gestation...
April 9, 2024: Lupus
#14
JOURNAL ARTICLE
Tabassum Elahi, Saima Ahmed, Muhammed Mubarak, Ejaz Ahmed
BACKGROUND: Pregnancy in women with systemic lupus erythematosus (SLE) has remained a great challenge for clinicians in terms of maternal and fetal outcomes. The outcomes in women with pre-existing lupus nephritis (LN) are variable. The impact of different classes of LN on maternal and fetal outcomes during pregnancy is not well defined, as data is very scarce, especially from the developing countries. METHODS: A retrospective analysis was conducted on 52 women with 89 pregnancies...
April 9, 2024: Lupus
#15
JOURNAL ARTICLE
Bronwyn D Power, Rangi Kandane-Rathnayake, Georgina Tiller, William D Renton, Angela Cox, Lilian Johnstone, Alberta Hoi, Peter Gowdie
INTRODUCTION: We aim to report on the feasibility of establishment of the first paediatric cohort as part of the longitudinal database of the Australian Lupus Registry and Biobank (ALRB) and to describe the enrolment data with a focus on clinical characteristics, serological data, treatment strategies and patient/parent-reported outcome measures. METHODS: All patients under the age of 18 years with a diagnosis of systemic lupus erythematosus (SLE) attending the paediatric rheumatology service of a single, tertiary hospital were identified...
April 8, 2024: Lupus
#16
JOURNAL ARTICLE
Ummusen Kaya Akca, Seher Sener, Ezgi Deniz Batu, Zeynep Balik, Ozge Basaran, Yelda Bilginer, Seza Ozen
BACKGROUND: Drug-induced lupus erythematosus (DILE) is the development of lupus-like syndrome following a drug exposure. DILE has been reported less frequently among children than adults. METHODS: In this study, we present four children with DILE and similar published cases through a systematic literature review. RESULTS: We report four children (three girls and one boy) who developed DILE associated with the use of topiramate, doxycycline, etanercept, and ethosuximide...
April 5, 2024: Lupus
#17
JOURNAL ARTICLE
Maria Galindo Izquierdo, Joaquín Borrás Blasco, Silvia Pérez Ortega, Tarek Carlos Salman-Monte, Paloma Vela-Casasempere, Esther Rodríguez Almaraz, Jaime Calvo-Alen, José María Álvaro-Gracia Álvaro, M Julia Barbado Ajo, Raül Rubio Renau, Marta Galvez-Fernandez, Noemí Bahamontes-Rosa, Joaquín Sánchez-Covisa Hernández, Carlota Solà Marsiñach
BACKGROUND AND OBJECTIVES: Systemic lupus erythematosus (SLE) is an autoimmune condition that can highly impact patients' quality of life (QoL). However, there is a lack of knowledge about SLE, affecting the general population and health care professionals (HCPs) alike. This lack of knowledge has negative implications for patients and the healthcare system, worsening prognosis, negatively impacting QoL, and increasing healthcare utilization. The aim of this paper is to draw attention, according to the perspective of the participants of this study, to the lack of awareness of SLE and its consequences in Spain, and to suggest improvements...
April 5, 2024: Lupus
#18
JOURNAL ARTICLE
Joanna Tingström, Elin Öst, Gunnar Bergman, Åsa Burström
OBJECTIVE: The aim of this study was to explore the parents' experiences of home monitoring of the fetal heart rhythm. Women with anti-SSA/Ro52 autoantibodies carry a 2%-3% risk of giving birth to a child with congenital heart block (CHB), following transplacental transfer and antibody-mediated inflammation in the fetal conduction system during 18th to 24th gestational week. Early detection and subsequent treatment have been reported to decrease morbidity and mortality. Therefore, home monitoring of the fetal heart rhythm by Doppler has been offered at our fetal cardiology center...
April 3, 2024: Lupus
#19
JOURNAL ARTICLE
Sofía Ornella, Lucila García, Máximo Cosentino, Marcelo F Taylor, Martín Ciappa, Mercedes A García
INTRODUCTION: Although RT has improved the survival of the population with ESRD due to all causes, renal outcomes in SLE are controversial. The objective of this study is to describe the characteristics and evolution of the patients and the kidney transplant in LN, and compare it with patients transplanted for other causes. MATERIALS AND METHODS: Retrospective, observational, analytical, single-center study in which records of patients undergoing nephrotransplantation for LN were analyzed...
April 3, 2024: Lupus
#20
JOURNAL ARTICLE
Halah Alfatlawi, Abdulmajeed Alharbi, Momin Shah, Yusuf Nawras, Nezam Altorok
INTRODUCTION: The existing literature offers limited insights into the influence of Libman-Sacks Endocarditis (LSE) on inpatient outcomes in individuals with Systemic Lupus Erythematosus (SLE). This study aimed to explore the characteristics and prognosis of SLE patients with LSE and the impact of LSE in patients with SLE on inpatient outcomes including inpatient mortality, length of stay, acute heart failure, atrial fibrillation, and cerebrovascular accidents (CVA). METHODS: This study included adult patients who were hospitalized with SLE between the years 2019 and 2020, using the National Inpatient Sample (NIS) database...
April 2, 2024: Lupus
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
